Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reactogenicity and immunogenicity of GSK Biologicals' influenza vaccine GSK576389A in elderly adults (greater than or equal to 66 years) previously vaccinated with the same candidate vaccine. Fluarix will be used as reference.

X
Trial Profile

Reactogenicity and immunogenicity of GSK Biologicals' influenza vaccine GSK576389A in elderly adults (greater than or equal to 66 years) previously vaccinated with the same candidate vaccine. Fluarix will be used as reference.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 576389A (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
  • Most Recent Events

    • 07 Sep 2008 Actual patient number (133) added as reported by ClinicalTrials.gov.
    • 29 Jan 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 16 Nov 2007 Status changed from recruiting to in progress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top